P49023 (PAXI_HUMAN) Homo sapiens (Human)
Paxillin UniProtKBInterProSTRINGInteractive Modelling
591 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4);
1 identical sequence: Homo sapiens: A0A140VJQ8
It is possible new templates exist for this target since these models were created.
Available Structures
22 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Solution structure of paxillin LIM4 in complex with kindlin-2 F0 |
Heteromer Q96AC1; | 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of GIT1 PBD domain in complex with Paxillin LD4 motif |
Heteromer Q9Z272; | |||||
| Assess | ||||||
| Crystal structure of human paxillin LD4 motif in complex with Fab fragment |
Heteromer | 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of the C-terminal calponin homology domain of alpha- parvin in complex with paxil… |
Heteromer Q9NVD7; | 1×PG4; 1×PGE; 5×EDO; | ||||
| Assess | ||||||
| Structural basis for the interaction of Pyk2 PAT domain with paxillin LD motifs |
Heteromer Q14289; | |||||
| Assess | ||||||
| Hydrocarbon-Stapled Paxillin Peptide Bound to the Focal Adhesion Targeting (FAT) Domain of the Foca… |
Heteromer Q05397; | 1×ZN; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of the C-terminal calponin homology domain of alpha- parvin in complex with paxil… |
Heteromer Q9NVD7; | 1×PG4; 2×EDO; 2×PGE; | ||||
| Assess | ||||||
| Crystal Structure of Paxillin NES Peptide in complex with CRM1-Ran-RanBP1 |
Heteromer P30822; P41920; P62826; | 1×GNP; 1×MG; 3×GOL; | ||||
| Assess | ||||||
| Crystal Structure of the Focal Adhesion Targeting (FAT) Domain of Pyk2 in Complex with Paxillin LD4… |
Heteromer Q14289; | |||||
| Assess | ||||||
| Crystal structure of the C-terminal calponin homology domain of alpha parvin in complex with paxill… |
Heteromer Q9NVD7; | 2×PGE; 1×PG4; 2×GOL; 2×EDO; | ||||
| Assess | ||||||
| Paxillin LD4 motif bound to the Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase |
Heteromer Q05397; | |||||
| Assess | ||||||
| Cerebral cavernous malformation 3 (CCM3) in complex with paxillin LD4 |
Heteromer Q9BUL8; | |||||
| Assess | ||||||
| Crystal structure of human paxillin LD2 motif in complex with Fab fragment |
Heteromer | 1×NO3; | ||||
| Assess | ||||||
| Paxillin LD4 motif bound to the Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase |
Heteromer Q05397; | |||||
| Assess | ||||||
| Paxillin LD2 motif bound to the Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase |
Heteromer Q05397; | |||||
| Assess | ||||||
| Crystal structure of beta-parvin CH2 domain in complex with paxillin LD1 motif |
Heteromer Q9HBI1; | |||||
| Assess | ||||||
| Cerebral cavernous malformation 3 (CCM3) in complex with paxillin LD2 |
Heteromer Q9BUL8; | |||||
| Assess | ||||||
| The second SH3 domain from Ponsin in complex with the paxillin proline rich region |
Heteromer Q9BX66; | |||||
| Assess | ||||||
| Cerebral cavernous malformation 3 (CCM3) in complex with paxillin LD1 |
Heteromer Q9BUL8; | |||||
| Assess | ||||||
| The NMR structure of alpha-parvin CH2/paxillin LD1 complex |
Heteromer Q9NVD7; | |||||
| Assess | ||||||
| Solution structure of paxillin LIM2/3 | monomer | 4×ZN; | ||||
| Assess | ||||||
| Solution structure of paxillin LIM4 | monomer | 2×ZN; | ||||
| Assess | ||||||
9 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7qb0.1.A | monomer | 0.62 | 4×ZN; | 100.00 | ||
| Assess | ||||||
| 7d2u.1.B | monomer | 0.58 | 1×ZN; | 36.13 | ||
| Assess | ||||||
| 1b8t.1.A | monomer | 0.53 | 26.05 | |||
| Assess | ||||||
| 6cme.1.A | monomer | 0.53 | 2×ZN; | 31.06 | ||
| Assess | ||||||
| 2ypa.1.C | monomer | 0.52 | 1×ZN; | 25.21 | ||
| Assess | ||||||
| 1b8t.1.A | monomer | 0.52 | 21.05 | |||
| Assess | ||||||
| 2rgt.2.A | monomer | 0.52 | 2×ZN; | 25.00 | ||
| Assess | ||||||
| 7qb0.1.A | monomer | 0.52 | 42.02 | |||
| Assess | ||||||
| 2rgt.2.A | monomer | 0.51 | 2×ZN; | 21.85 | ||
| Assess | ||||||
21 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 7lt9.1.B | monomer | 0.57 | 1×ZN; | 35.90 | |
| Assess | ||||||
| Isoform 2 | 7qb0.1.A | monomer | 0.57 | 4×ZN; | 100.00 | |
| Assess | ||||||
| Isoform 2 | 1b8t.1.A | monomer | 0.53 | 26.05 | ||
| Assess | ||||||
| Isoform 2 | 6cme.1.A | monomer | 0.51 | 2×ZN; | 31.06 | |
| Assess | ||||||
| Isoform 2 | 2rgt.2.A | monomer | 0.51 | 1×ZN; | 25.00 | |
| Assess | ||||||
| Isoform 2 | 7qb0.1.A | monomer | 0.51 | 42.02 | ||
| Assess | ||||||
| Isoform 2 | 2ypa.1.C | monomer | 0.50 | 1×ZN; | 25.21 | |
| Assess | ||||||
| Isoform 2 | 1b8t.1.A | monomer | 0.50 | 21.05 | ||
| Assess | ||||||
| Isoform 3 | 7qb0.1.A | monomer | 0.63 | 4×ZN; | 100.00 | |
| Assess | ||||||
| Isoform 3 | 7d2u.1.B | monomer | 0.58 | 1×ZN; | 36.13 | |
| Assess | ||||||
| Isoform 3 | 1b8t.1.A | monomer | 0.54 | 26.05 | ||
| Assess | ||||||
| Isoform 3 | 6cme.1.A | monomer | 0.53 | 2×ZN; | 31.06 | |
| Assess | ||||||
| Isoform 3 | 2ypa.1.C | monomer | 0.52 | 1×ZN; | 25.21 | |
| Assess | ||||||
| Isoform 3 | 1b8t.1.A | monomer | 0.52 | 21.05 | ||
| Assess | ||||||
| Isoform 3 | 7qb0.1.A | monomer | 0.52 | 42.02 | ||
| Assess | ||||||
| Isoform 3 | 2rgt.2.A | monomer | 0.52 | 1×ZN; | 25.00 | |
| Assess | ||||||
| Isoform 3 | 2rgt.2.A | monomer | 0.50 | 2×ZN; | 21.85 | |
| Assess | ||||||
| Isoform 4 | 7d2t.1.B | monomer | 0.60 | 1×ZN; | 36.13 | |
| Assess | ||||||
| Isoform 4 | 7qb0.1.A | monomer | 0.57 | 4×ZN; | 100.00 | |
| Assess | ||||||
| Isoform 4 | 1b8t.1.A | monomer | 0.52 | 26.05 | ||
| Assess | ||||||
| Isoform 4 | 7qb0.1.A | monomer | 0.51 | 34.45 | ||
| Assess | ||||||